{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T22:11:47Z","timestamp":1763244707078,"version":"build-2065373602"},"reference-count":50,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Transarterial radioembolization is a well-established method for the treatment of hepatocellular carcinoma. The tolerability and incidence of hepatic decompensation are related to the doses delivered to the tumor and healthy liver. This retrospective study was performed at our center to evaluate whether tumor- and healthy-liver-absorbed dose levels in TARE are predictive of tumor response according to the mRECIST 1.1 criteria and overall survival. One hundred and six patients with hepatocellular carcinoma were treated with [90Y]-loaded resin microspheres and completed the follow-up. The dose delivered to each compartment was calculated using a compartmental model. The model was based on [99mTc]-labelled albumin aggregate images obtained before the start of therapy. Tumor response was assessed after three months of treatment. Kaplan-Meier analysis was used to assess survival. The mean age of our population was 66 \u00b1 13 years with a majority being BCLC B tumors. Forty-two patients presented with portal vein thrombosis. The response rate was 57% in the overall population and 59% in patients with thrombosis. Target-to-background (TBR) values measured on initial [99mTc]MAA-SPECT-imaging and tumor model dosimetric values were associated with tumor response (p &lt; 0.001 and p = 0.009, respectively). A dosimetric threshold of 136.5 Gy was predictive of tumor response with a sensitivity of 84.2% and specificity of 89.4%. Overall survival was 24.1 months [IQR 13.1\u201336.4] for patients who responded to treatment compared to 10.4 months [IQR 6.3\u201315.9] for the remaining patients (p = 0.022). In this cohort, the initial [99mTc]MAA imaging is predictive of response and survival. The dosimetry prior to the application of TARE can be used for treatment planning and our results also suggest that the therapy is well-tolerated. In particular, hepatic decompensation can be predicted even in the presence of PVT.<\/jats:p>","DOI":"10.3390\/diagnostics13142432","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T01:52:35Z","timestamp":1689904355000},"page":"2432","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive Value of [99mTc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [90Y]-TARE: A Single-Center Experience"],"prefix":"10.3390","volume":"13","author":[{"given":"Michael","family":"Doppler","sequence":"first","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlene","family":"Reincke","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-8729","authenticated-orcid":false,"given":"Dominik","family":"Bettinger","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Vogt","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schultheiss","sequence":"additional","affiliation":[{"name":"Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany"},{"name":"Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6756-9005","authenticated-orcid":false,"given":"Wibke","family":"Uller","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8424-5827","authenticated-orcid":false,"given":"Niklas","family":"Verloh","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9524-0813","authenticated-orcid":false,"given":"Christian","family":"Goetz","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1055\/a-1589-7585","article-title":"S3-Leitlinie: Diagnostik und Therapie des hepatozellul\u00e4ren Karzinoms und bili\u00e4rer Karzinome\u2013Version 2.0\u2013Juni 2021, AWMF-Registernummer: 032-053OL","volume":"60","author":"Voesch","year":"2022","journal-title":"Z. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Somma, F., Stoia, V., Serra, N., D\u2019Angelo, R., Gatta, G., and Fiore, F. (2019). Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216935"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients with Hepatocellular Carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/cncr.24884","article-title":"Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: A Two-Cohort Study","volume":"116","author":"Carr","year":"2010","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00259-015-3157-8","article-title":"Clinical impact of (99m)Tc-MAA SPECT\/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres","volume":"43","author":"Garin","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00259-008-0857-3","article-title":"Radioembolisation with 90Y-microspheres: Dosimetric and radiobiological investigation for multi-cycle treatment","volume":"35","author":"Cremonesi","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","first-page":"503","article-title":"A dosimetric treatment planning strategy in radio-embolization of hepatocarcinoma with 90Y glass microspheres","volume":"56","author":"Chiesa","year":"2012","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"21245","DOI":"10.1097\/MNM.0b013e32834a716b","article-title":"Effectiveness of quantitative MAA SPECT\/CT for the definition of vascularized hepatic volume and dosimetric approach: Phantom validation and clinical preliminary results in patients with complex hepatic vascularization treated with yttrium-90-labeled microspheres","volume":"32","author":"Garin","year":"2011","journal-title":"Nucl. Med. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2967\/jnumed.111.097469","article-title":"Image-guided personalized predictive dosimetry by artery-specific SPECT\/CT partition modeling for safe and effective 90Y radioembolization","volume":"53","author":"Kao","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00270-011-0295-7","article-title":"Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: Sequential lobar versus whole liver approach","volume":"35","author":"Seidensticker","year":"2012","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2967\/jnumed.114.145177","article-title":"Personalized dosimetry and intensification concept with 90Y-loaded glass microsphere radioembolization induce prolonged overall survival in hepatocelluar carcinoma patients with portal vein thrombosis","volume":"56","author":"Garin","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00270-022-03215-x","article-title":"Trans-arterial Radioembolization Dosimetry in 2022","volume":"45","author":"Garin","year":"2022","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mahvash, A., Chartier, S., Turco, M., Habib, P., Griffith, S., Brown, S., and Kappadath, S.C. (2022). A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: The DOORwaY90 (Duration of Objective Response with arterial Ytrrium-90) study. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02204-1"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1002\/hep4.2072","article-title":"Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma","volume":"6","author":"Reincke","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2967\/jnumed.111.094235","article-title":"99mTc-MAA SPECT\/CT based dosimetry accurately predicts tumour response and survival in HCC patients treated with 90Y-loaded glass microspheres: Preliminary results","volume":"53","author":"Garin","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","article-title":"International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres","volume":"48","author":"Levillain","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_20","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jvir.2010.10.029","article-title":"Technology Assessment Committee; Interventional Oncology Task Force of the Society of Interventional Radiology. Research reporting standards for radioembolization of hepatic malignancies","volume":"22","author":"Salem","year":"2011","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00259-011-1812-2","article-title":"Therapy. Oncology and Dosimetry Committees. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds","volume":"38","author":"Giammarile","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijrobp.2010.08.015","article-title":"Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin micro-spheres","volume":"82","author":"Lau","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.tvir.2007.08.001","article-title":"Technical aspects of radioembolization with 90Y microspheres","volume":"10","author":"Salem","year":"2007","journal-title":"Tech. Vasc. Interv. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/01.RVI.0000233785.75257.9A","article-title":"Radioembolization with 90Yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations","volume":"17","author":"Salem","year":"2006","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/BF01084369","article-title":"Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours","volume":"23","author":"Ho","year":"1996","journal-title":"Eur. J. Nucl Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/01.RVI.0000184594.01661.81","article-title":"Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, and survival","volume":"16","author":"Salem","year":"2005","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/01.RVI.0000179815.44868.66","article-title":"90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: Response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging","volume":"16","author":"Lewandowski","year":"2005","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ijrobp.2005.12.051","article-title":"Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience","volume":"65","author":"Kennedy","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_32","first-page":"293","article-title":"Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer","volume":"24","author":"Ho","year":"1997","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_33","first-page":"1209","article-title":"Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations","volume":"47","author":"Gulec","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: Performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.2967\/jnumed.116.173104","article-title":"Partition model-based 99mTc-MAA SPECT\/CT predictive dosimetry compared with 90Y TOF PET\/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: A quantitative agreement comparison","volume":"57","author":"Gnesin","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejmp.2021.07.032","article-title":"Accurate non-tumoural 99mTc-MAA absorbed dose prediction to plan optimized activities in liver radioembolization using resin microspheres","volume":"89","author":"Walrand","year":"2021","journal-title":"Phys. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13550-020-00675-5","article-title":"Quantitative comparison of pre-treatment predictive and post-treatment measured dosimetry for selective internal radiation therapy using cone-beam CT for tumour and liver perfusion territory definition","volume":"10","author":"Tang","year":"2020","journal-title":"EJNMMI Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.2967\/jnumed.115.162685","article-title":"Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors","volume":"56","author":"Ilhan","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2967\/jnumed.112.117614","article-title":"99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization","volume":"54","author":"Wondergem","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/153303461000900304","article-title":"Quantitative comparison of yttrium-90 (90Y)-microspheres and technetium-99m (99mTc)-macroaggregated albumin SPECT images for planning 90Y therapy of liver cancer","volume":"9","author":"Knesaurek","year":"2010","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/2191-219X-3-57","article-title":"Post-radioembolization yttrium-90 PET\/CT\u2014Part 2: Dose-response and tumor predictive dosimetry for resin microspheres","volume":"3","author":"Kao","year":"2013","journal-title":"EJNMMI Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3389\/fonc.2014.00255","article-title":"Determination of radiation absorbed dose to primary liver tumors and normal liver tissue using post-radioembolization 90Y PET","volume":"4","author":"Srinivas","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejmp.2019.05.025","article-title":"PET-CT post therapy dosimetry in radioembolization with resin 90Y microspheres: Comparison with pre-treatment SPECT\/CT 99mTc-MAA results","volume":"64","author":"Richetta","year":"2019","journal-title":"Phys. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","article-title":"Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival","volume":"52","author":"Hilgard","year":"2010","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2967\/jnumed.112.112508","article-title":"Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres","volume":"54","author":"Ulrich","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13550-014-0033-7","article-title":"Personalized predictive lung dosimetry by technetium-99m macroaggregated albumin SPECT\/CT for yt trium-90 radioembolization","volume":"4","author":"Kao","year":"2014","journal-title":"EJNMMI Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/cncr.23339","article-title":"Liver disease induced by radioembolization of liver tumors: Description and possible risk factors","volume":"112","author":"Sangro","year":"2008","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1007\/s00259-020-04845-4","article-title":"Radioembolization of hepatocarcinoma with 90Y glass microspheres: Treatment optimization using the dose-toxicity relationship","volume":"47","author":"Chiesa","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_50","first-page":"168","article-title":"Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with 90Y microspheres: The experience of the National Tumor Institute of Milan","volume":"55","author":"Chiesa","year":"2011","journal-title":"Q. J. Nucl. Med. Mol. Imaging"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/14\/2432\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:16:03Z","timestamp":1760127363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/14\/2432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":50,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["diagnostics13142432"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13142432","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2023,7,20]]}}}